News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
717,893 Results
Type
Article (40687)
Company Profile (270)
Press Release (676930)
Multimedia
Podcasts (76)
Webinars (17)
Section
Business (204573)
Career Advice (2019)
Deals (35508)
Drug Delivery (105)
Drug Development (81316)
Employer Resources (173)
FDA (16377)
Job Trends (14930)
News (346177)
Policy (32704)
Tag
Academia (2558)
Accelerated approval (24)
Adcomms (24)
Allergies (123)
Alliances (49583)
ALS (158)
Alzheimer's disease (1623)
Antibody-drug conjugate (ADC) (268)
Approvals (16567)
Artificial intelligence (454)
Autoimmune disease (116)
Automation (33)
Bankruptcy (361)
Best Places to Work (11638)
BIOSECURE Act (20)
Biosimilars (174)
Biotechnology (176)
Bladder cancer (147)
Brain cancer (52)
Breast cancer (591)
Cancer (4411)
Cardiovascular disease (360)
Career advice (1701)
Career pathing (34)
CAR-T (261)
CDC (44)
Celiac Disease (1)
Cell therapy (683)
Cervical cancer (35)
Clinical research (69031)
Collaboration (1472)
Company closure (4)
Compensation (1040)
Complete response letters (46)
COVID-19 (2695)
CRISPR (81)
C-suite (688)
Cystic fibrosis (136)
Data (5708)
Decentralized trials (2)
Denatured (25)
Depression (112)
Diabetes (458)
Diagnostics (6604)
Digital health (38)
Diversity (11)
Diversity, equity & inclusion (45)
Drug discovery (216)
Drug pricing (166)
Drug shortages (28)
Duchenne muscular dystrophy (212)
Earnings (89729)
Editorial (50)
Employer branding (21)
Employer resources (151)
Events (116582)
Executive appointments (937)
FDA (19125)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (7)
Frontotemporal dementia (20)
Funding (1327)
Gene editing (180)
Generative AI (38)
Gene therapy (538)
GLP-1 (916)
Government (4625)
Grass and pollen (6)
Guidances (376)
Healthcare (18859)
HIV (48)
Huntington's disease (39)
IgA nephropathy (75)
Immunology and inflammation (229)
Immuno-oncology (37)
Indications (76)
Infectious disease (2938)
Inflammatory bowel disease (179)
Inflation Reduction Act (13)
Influenza (103)
Intellectual property (209)
Interviews (315)
IPO (16621)
IRA (48)
Job creations (3640)
Job search strategy (1427)
Kidney cancer (15)
Labor market (79)
Layoffs (542)
Leadership (29)
Legal (7943)
Liver cancer (88)
Longevity (12)
Lung cancer (609)
Lymphoma (350)
Machine learning (37)
Management (59)
Manufacturing (673)
MASH (153)
Medical device (13687)
Medtech (13724)
Mergers & acquisitions (19850)
Metabolic disorders (1144)
Multiple sclerosis (143)
NASH (16)
Neurodegenerative disease (276)
Neuropsychiatric disorders (69)
Neuroscience (2705)
NextGen: Class of 2025 (6518)
Non-profit (4501)
Now hiring (61)
Obesity (529)
Opinion (248)
Ovarian cancer (149)
Pain (173)
Pancreatic cancer (193)
Parkinson's disease (253)
Partnered (31)
Patents (445)
Patient recruitment (398)
Peanut (54)
People (58528)
Pharmaceutical (63)
Pharmacy benefit managers (26)
Phase I (21512)
Phase II (30383)
Phase III (22658)
Pipeline (3837)
Policy (260)
Postmarket research (2564)
Preclinical (9165)
Press Release (64)
Prostate cancer (215)
Psychedelics (43)
Radiopharmaceuticals (264)
Rare diseases (710)
Real estate (5948)
Recruiting (69)
Regulatory (23951)
Reports (51)
Research institute (2372)
Resumes & cover letters (351)
Rett syndrome (23)
RNA editing (12)
RSV (73)
Schizophrenia (134)
Series A (217)
Series B (166)
Service/supplier (11)
Sickle cell disease (91)
Special edition (20)
Spinal muscular atrophy (153)
Sponsored (40)
Startups (3607)
State (2)
Stomach cancer (16)
Supply chain (97)
Tariffs (80)
The Weekly (49)
Vaccines (946)
Venture capital (75)
Weight loss (342)
Women's health (74)
Worklife (17)
Date
Today (98)
Last 7 days (525)
Last 30 days (2356)
Last 365 days (30236)
2025 (29762)
2024 (35220)
2023 (40076)
2022 (51174)
2021 (55712)
2020 (54084)
2019 (46538)
2018 (35020)
2017 (32108)
2016 (31480)
2015 (37555)
2014 (31318)
2013 (26348)
2012 (28570)
2011 (29267)
2010 (27329)
Location
Africa (734)
Alabama (77)
Alaska (7)
Arizona (289)
Arkansas (13)
Asia (38964)
Australia (6363)
California (10404)
Canada (3091)
China (974)
Colorado (435)
Connecticut (445)
Delaware (310)
Europe (83955)
Florida (1542)
Georgia (331)
Hawaii (2)
Idaho (61)
Illinois (781)
India (54)
Indiana (492)
Iowa (20)
Japan (368)
Kansas (122)
Kentucky (36)
Louisiana (24)
Maine (70)
Maryland (1307)
Massachusetts (7501)
Michigan (301)
Minnesota (587)
Mississippi (5)
Missouri (121)
Montana (30)
Nebraska (26)
Nevada (112)
New Hampshire (73)
New Jersey (2803)
New Mexico (28)
New York (2770)
North Carolina (1357)
North Dakota (8)
Northern California (4996)
Ohio (306)
Oklahoma (20)
Oregon (38)
Pennsylvania (2133)
Puerto Rico (19)
Rhode Island (45)
South America (1100)
South Carolina (58)
South Dakota (1)
Southern California (4027)
Tennessee (163)
Texas (1601)
United States (37170)
Utah (308)
Vermont (1)
Virginia (239)
Washington D.C. (78)
Washington State (854)
West Virginia (4)
Wisconsin (90)
Wyoming (2)
717,893 Results for "shionogi inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
FDA Accepts Shionogi’s Ensitrelvir NDA as the First Oral Therapy for the Prevention of COVID-19 Following Exposure
September 3, 2025
·
9 min read
Press Releases
IDWeek 2025: Shionogi Presents Real-World and Surveillance Data Reinforcing Role of Cefiderocol Across Range of Patient Populations and Difficult-to-Treat Infections
October 20, 2025
·
17 min read
Press Releases
BioVersys and Shionogi Enter Into Global Research Collaboration For Broad-Spectrum Non-Tuberculous Mycobacteria (NTM) Clinical Candidate
July 2, 2025
·
8 min read
Business
Akili Announces Amended Agreement with Shionogi, Shift in Corporate Strategy and Release Date for First Quarter 2024 Financial Results
Akili, Inc. including an amendment to its strategic distribution agreement with Shionogi & Co., Ltd. (“Shionogi”), a leading global pharmaceutical company.
April 30, 2024
·
9 min read
Business
Shionogi & Co., Ltd. and Maze Therapeutics, Inc. Announce Exclusive Worldwide License Agreement for MZE001, a Novel Therapeutic Candidate for the Treatment of Pompe Disease
Shionogi & Co., Ltd. and Maze Therapeutics, Inc. announced the companies have completed an exclusive worldwide license agreement for the rights to MZE001, an investigational oral glycogen synthase 1 inhibitor that aims to address Pompe disease by limiting disease-causing glycogen buildup.
May 10, 2024
·
6 min read
Deals
Shionogi Further Extends Infectious Disease Innovation Platform with Planned Acquisition of Qpex Biopharma, Inc.
Shionogi & Co., Ltd. announced that Shionogi Inc., a New Jersey-based subsidiary of Shionogi, has entered into a definitive agreement pursuant to which Shionogi Inc. will acquire Qpex Biopharma, Inc.
June 26, 2023
·
7 min read
Business
Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx® for Pediatric ADHD Patients in Japan
Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx® for Pediatric ADHD Patients in Japan.
February 26, 2024
·
7 min read
Business
Shionogi Strengthens Regulatory Leadership with the Appointment of Dr. Ramón Polo as Senior Vice President, Head of Regulatory Affairs
Shionogi Inc., a U.S. subsidiary of Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Isao Teshirogi, Ph.D.; hereinafter “Shionogi”), announced the appointment of Ramón Polo, MBA, PharmD, Ph.D. as Senior Vice President, Head of Regulatory Affairs.
February 5, 2024
·
4 min read
Pharm Country
IDWeek 2023: Shionogi and Qpex Biopharma, Inc. Continue Longstanding Commitment to Addressing Unmet Needs in Infectious Disease
Shionogi Inc., the United States subsidiary of Shionogi & Co., Ltd., announced the upcoming presentation of new data at IDWeek 2023 on its investigational oral antiviral for COVID-19, ensitrelvir, and Fetroja®, an antibiotic marketed under the brand name Fetcroja® in Europe.
September 7, 2023
·
7 min read
Shionogi Expands Global Infectious Disease and Antimicrobial Research Operations to U.S. to Address Current and Emerging Health Threats
Shionogi & Co., Ltd. announced the company is responding to the urgent global need for additional antimicrobial research and development by establishing its first discovery laboratory in the U.S., in San Diego, California.
June 3, 2024
·
9 min read
1 of 71,790
Next
